Group Health Premarin-to-EstraTab switch has 83.4% conversion rate after six months.
GROUP HEALTH PREMARIN-TO-ESTRATAB SWITCH HAS 83.4% SUCCESS RATE among the 16,364 Group Health enrollees previously receiving Wyeth-Ayerst's Premarin (conjugated estrogens), Group Health Cooperative of Puget Sound Medication Use Management Director William Baluch reported at the American Society of Health-System Pharmacists mid-year clinical meeting Dec. 10 in New Orleans. The health plan switched 14,601 Premarin users (89.2%) to Solvay's estrogen replacement therapy EstraTab (esterified estrogens). After six months, 13,654 patients (83.4% of the original Premarin users) continued on EstraTab therapy, while 2,710 either were never switched from Premarin or had switched back to the Wyeth drug. The switch program began in the summer of 1991.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth